TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study.~* Male or female ≥ 8 years old.~* Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization.~* Woman of childbearing potential (WOCBP) must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study.~* Subject is non-pregnant and non-lactating.~* Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target and Non-Target Warts or which exposes the subject to an unacceptable risk by study participation.~* Subject is willing and able to follow all study instructions and to attend all study visits.~Exclusion Criteria:~* Subject has clinically atypical warts on the trunk or extremities.~* Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.)~* Subject has a history of Human Immunodeficiency Virus (HIV) infection~* Subject has had any Human Papilloma Virus (HPV) vaccine within 1 year prior to Visit 1~* Subject has a history of sensitivity to any of the ingredients in the study medications.~* Subject has any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.~* Participation in another therapeutic investigational drug trial in which administration of an investigational study medication occurred with 30 days prior to Visit 1.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): A-101 Topical Solutions
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females, no child-bearing potential or negative urine pregnancy test on day of BAY94-9172 injection~* Exhibits visual, auditory, and communicative capabilities adequate to provide informed consent or assent and comply with study procedures~* Is willing and able to lie down in magnetic resonance imaging (MRI) and positron emission tomography (PET) scanners~* Is willing to donate their brain for postmortem examination in case of death~* The subject, or the subject and/or legally acceptable representative will be compliant and have a high probability of completing the study in the opinion of the investigator~* Has been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA), as applicable, and informed consent or assent has been signed and dated (with time) by the subject and/or the subject's legally acceptable representative~* The subjects who have participated in a previous florbetaben study e.g. study 311741 may be included in the present study. The MRI- and florbetaben PET scan do not need to be repeated if both scans were performed within twelve months prior to inclusion.~Exclusion Criteria:~* Has severe cerebral macrovascular (ie, multi-stroke) disease or brain tumor (metastasis/brain cancer) as verified by MRI~* Has any contraindication to magnetic resonance imaging (MRI) examination, eg, metal implants or phobia as determined by the onsite radiologist performing the scan~* Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study~* Has severe cardio-vascular instability requiring intensive care surveillance and/or therapeutic intervention (i.e. catecholamine infusion)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Florbetaben (BAY94-9172) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age with a diagnosis of Relapse Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)~* Currently injecting glatiramer acetate 20 mg/1.0 mL per day subcutaneously (SC) for a minimum of 90 days utilizing the autoject 2 for glass syringe for a minimum of 75% of daily injections~* Willing and able to complete all procedures and evaluations related to the study~* Willing to continue to follow usual injection site preparation and routine adjunctive local injection site reactions (LISR) management techniques~* Willing and able to provide written informed consent~Exclusion Criteria:~* Currently using or treated with another immunomodulating therapy (IMT) in conjunction with GA in the 30 days prior to screening for this study~* Currently using an investigational drug or using treatment with any other investigational agent in the 30 days prior to screening for this study~* Pregnant or planning pregnancy or breastfeeding~* Use of any other parenteral medications (e.g., intramuscular, SC, intravenous, etc.) either currently or in the past 30 days prior to screening for this study~* Any other medical or psychiatric conditions that would make the patient unsuitable for this research, as determined by the Investigator~* Unwilling to perform all daily injections with an autoject 2 device~* Previous participation in any study evaluating the new 20 mg/0.5 mL formulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 mg/0.5 mL Glatiramer Acetate (Type: ACTIVE_COMPARATOR): Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically diagnosed onychomycosis of the target nail~* Presence of mild to moderate onychomycosis, defined as 20 - 50% of the area of the target nail being clinically affected~* Has a positive KOH examination from the target nail~* Has a positive dermatophyte culture from the target nail~Exclusion Criteria:~* Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug~* Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis~* Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit~* Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IDP-108 (Type: EXPERIMENTAL): None
- Vehicle (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Phase IVb of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects (6-71 months old children)~* The subjects' legal guardian voluntarily participate in the study and signed Informed Consent Form~* The subjects' legal guardian with the ability and objective to comply with the requirements of the protocol~Exclusion Criteria:~* Allergy to a vaccine , any ingredient of vaccine or substance used in the preparation process including excipients, formaldehyde, and kanamycin sulfate.~* Fever, acute illness~* Severe chronic disease, allergic diathesis

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- vaccine (3.0 EU) (Type: EXPERIMENTAL): healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Men or women, age 18 to 50 years (inclusive) without significant medical history, physical or clinical lab abnormalities (as per protocol defined ranges)~* Women of childbearing potential must have negative urine pregnancy test and must be willing to use adequate birth control for 2 months following vaccination and have additional pregnancy tests as indicated~* Vaccinees must live alone or have no more than two household contacts willing to sign informed consent and participate in the study~* Household contacts must be healthy (based on medical history) men or women aged 18-65 years (inclusive)~Exclusion Criteria:~* Healthcare workers who have direct contact with patients who are immunodeficient, are HIV-positive, have unstable medical condition or are under the age of 18~* Childcare workers who have direct contact with children who are 2 years of age or younger or those employed in the food service industry~* Resides with HHCs who are under the age of 18 or over the age of 65~* Has abnormal stool pattern defined as fewer than 3 stools per week or more than 2 stools per day in past 6 months~* Has known allergy to, or known medical condition that precludes the use of both tetracycline or ciprofloxacin~* Previously received a licensed or investigational cholera vaccine~* Has history of cholera or enterotoxigenic E. coli infection (natural infection or experimental challenge)~* Travel to a cholera-endemic area and experienced symptoms consistent with traveler's diarrhea in the previous 5 years~* Received or plans to receive any other licensed vaccines from 14 days prior to the study vaccination until Day 28~* Received or plans to receive antibiotics (other than protocol-specified) or chloroquine within 14 days prior to the study vaccination through to Day 28

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PXVX0200 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients.~* Positive EGFR Mutation.~* No previous systemic anticancer therapy.~* Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site.~* Provision of written informed consent.~Exclusion Criteria:~* Experience of Anti-EGFR(the epidermal growth factor receptor) Monoclonal Antibody or small molecular compounds therapy such as gefitinib, erlotinib or Cetuximab.~* Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).~* Known severe hypersensitivity to icotinib or any of the excipients of this product.~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): Icotinib 125mg is administered orally three times per day.
- Chemotherapy (Type: ACTIVE_COMPARATOR): Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proven adenocarcinoma of the prostate~* Stage: cT1c-3b N0M0 according to American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM)~* Prostatic Specific Antigen (PSA)\<100 ng/ml~* Intermediate (T1-T2 with Gleason Score \[GS\] 7 and/or PSA 10-20)~* High risk (T3 and/or GS 8-10 and/or PSA \> 20)~* Karnofsky Index (KI) performance status ≥70%~* Written informed consent~Exclusion Criteria:~* T4 N1 M1,~* Previous surgical treatment (prostatectomy or cryosurgery)~* Neoadjuvant hormonal treatment \> 3 months.~* History of pelvic radiotherapy (RT)~* Contraindications for radiotherapy~* Concomitant use of chemotherapy~* Serious psychiatric or medical condition~* Current synchronic malignancies

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Long term androgen deprivation (Type: EXPERIMENTAL): * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* High dose conformal radiotherapy~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
- Short term androgen deprivation (Type: ACTIVE_COMPARATOR): * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* High dose conformal radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A new diagnosis of diabetic nephropathy proved by histology and(or) serology.~2. Proteinuria \> 2.5 g/24 h~3. serum creatinine \< 3 mg/dl~4. age 35-65 years~Exclusion Criteria:~1. Co-existence of anther chronic glomerular nephritis.~2. Severe disfunction of the liver~3. White blood cell \< 3000/ul~4. Severe infection in the past 1 month~5. Malignant hypertension which in hard to control~6. Myocardial infarct or heart failure or sever cerebral vessels complication in the past 6 month

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- immunosuppressor (Type: EXPERIMENTAL): Valsartan,160mg/d,TW 120mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus~Exclusion Criteria:~* Patients with type 1 diabetes mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo QD 12-week
- 2 (Type: EXPERIMENTAL): 25 mg QD 12-week
- 3 (Type: EXPERIMENTAL): 50 mg QD 12-week
- 4 (Type: EXPERIMENTAL): 100 mg QD 12-week
- 5 (Type: EXPERIMENTAL): 200 mg QD 12-week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Meets DSM-IV criteria for both alcohol and cocaine dependence, as determined by the Structured Clinical Interview(SCID-IV)~* Successful completion of alcohol detoxification (i.e., 3 consecutive days of abstinence from alcohol)~* Use of at least $100 worth of cocaine in the 30 days prior to enrollment~* In the past 30 days, Subject used no less than $100 worth of cocaine and drank a minimum of 12 standard alcohol drinks/week (on average), having at least four days in 30 where at least four or more drinks were ingested, as determined by the Timeline Followback (TLFB) - adapted to collect daily cocaine use;~* Able to commute to the treatment research center~* Speaks, understands, and writes English~* Understands and signs the informed consent.~Exclusion Criteria:~* Abstinence from alcohol or cocaine for more than 30 days before signing consent form~* Current DSM-IV diagnosis of any psychoactive substance dependence other than Alcohol, Cocaine or Nicotine dependence, as determined by the SCID;~* Evidence of opiate use in the past 30 days as assessed by self-report and intake urine drug screen;~* History of unstable or serious medical illness, including need for opioid analgesics;~* Concomitant treatment with phenytoin or from same drug class, lithium, serotonin selective reuptake inhibitors, tricyclic antidepressants, MAOI's or narcotics; 6) Use of any investigational medication within the past 30 days;~* Severe physical or medical illness such as AIDS, active hepatitis or significant hepatocellular injury as evidenced by elevated bilirubin levels;~* Severe psychiatric symptoms, e.g., psychosis, suicidal or homicidal ideation or mania;~* Female patients who are pregnant, nursing, or not using a reliable method of contraception. Acceptable methods of birth control include: barrier (diaphragm or condom) with spermicide, intrauterine progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, oral contraceptives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): Naltrexone
- Disulfiram (Type: EXPERIMENTAL): Disulfiram
- Naltrexone and Disulfiram (Type: EXPERIMENTAL): Naltrexone and Disulfiram
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Cisplatin in Early Stage Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All tumors must be ER-, PR- and HER-2 negative.~* Age \> 18 years~* ECOG performance status of less than or equal to 1~* Absolute neutrophil count (ANC) \> 1,500/mm3~* Hemoglobin \> 9mm/dl~* Platelets \> 100,000/mm3~* Creatinine \< 1.5mg/dl~* Glucose \< 200mg/dl~* Bilirubin \< 1.5 x upper limit of normal (ULN)~* SGOT \< 3.0 x ULN~Exclusion Criteria:~* Prior chemotherapy treatment~* Pregnant or breast-feeding women~* History of serious illness, medical or psychiatric condition requiring medical management~* Uncontrolled infection~* Renal dysfunction~* Active or severe cardiovascular or pulmonary disease~* Peripheral neuropathy of any etiology that exceeds grade 1~* Prior history of malignancy~* Uncontrolled diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention single arm (Type: EXPERIMENTAL): Cisplatin 75mg/m2 q21 days x 4 pre-surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete